Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria

摘要: Background: Monoclonal anti-IgE antibody omalizumab is a promising therapeutic option in patients with chronic urticaria (CU) resistant to non-sedating H1-antihistamines (nsAH). However, data about its long-term efficacy and safety are still scant. Objective: We retrospectively analysed the clinical course of severe recalcitrant CU that were treated our department for period greater than 24 months. Methods patients: Seven (six females, median 43 years) 35 months have been evaluated. Before treatment, all suffered from persistent symptoms despite receiving high doses nsAH [4×/day], leukotriene antagonists prednisolone (10---30 mg/day duration 48 months). Response treatment was assessed using activity score (UAS) combined symptom/medication score. Results: There complete remission disease four after first dose omalizumab. 5th administration, had UAS 0. found significant improvement between pre-treatment (p = 0.017) gradual decrease over five administrations. Tapering possible patients. Administration intervals gradually increased, although experienced resurgence cycles six weeks. no reported adverse reactions attributable drug. Conclusion: Omalizumab safe effective corticosteroid alternative maintaining these Treatment required individual patient-by-patient determination. The drug did not seem alter natural history disease.